Lauryl M. J. Nutter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lauryl M. J. Nutter has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Martin Hrabě de Angelis
Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
19 shared publications - Kevin C. Kent Lloyd
Mouse Biology Program, University of California, Davis, CA 95616, USA
18 shared publications - Yann Herault
Université of Strasbourg, CNRS, INSERM, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), UMR7104 U1258, 1 Rue Laurent Fries, 67404 Illkirch, France; Université of Strasbourg, CNRS, INSERM, PHEN-ICS, UAR2062, US66, Illkirch, France; CNRS, CELPHEDIA Core, UAR2052, US66, Villejuif, France
18 shared publications Ann-Marie Mallon
MRC Harwell Institute, Harwell, UK
15 shared publications- Colin McKerlie
The Centre for Phenogenomics, Toronto, ON, M5T 3H7, Canada
12 shared publications Ann M. Flenniken
11 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Wiley in Hippocampus
- Vol. 36 (5) , e70129
Cover Image, Volume 36, Issue 5
- 9 September 2026
- Published by Wiley in Hippocampus
- Vol. 36 (5) , e70129
Open AccessCover Image, Volume 36, Issue 5
- Open Access
- 28 August 2026
- Published by Wiley in Hippocampus
- Vol. 36 (5)
Diurnal Regulation of Hippocampal Synaptic Plasticity in Aged Rats and the Role of the Circadian Clock Gene Per1
Period circadian regulator 1 (PER1) regulates circadian gene expression and is critical for spatial memory. However, its role in regulating synaptic plasticity between diurnal phases remains largely unknown. Here, we examined long‐term potentiation (LTP) and long‐term synaptic depression (LTD) in hippocampal slices prepared from aged male Per1 knockout ( Per1 KO) rats and their wildtype (WT) littermates during the light/inactive and dark/active phases. In WT rats, theta‐burst stimulation (TBS) consistently induced stable LTP that was greater during the dark relative to the light phase. In contrast, in Per1 KO rats, TBS resulted in synaptic potentiation that decayed to baseline levels within ~90 min in both phases. Notably, WT rats readily expressed LTD following 1 Hz low‐frequency stimulation (LFS) during the dark phase but not the light phase. By comparison, in Per1 KO rats, LTD was inducible by LFS during both the dark and light phases. LTD in both WT and Per1 KO rats was dependent on the activation of N ‐methyl‐ d ‐aspartate receptors. Basal synaptic transmission was reduced and GluA1 S845 phosphorylation was increased during the dark phase in both WT and Per1 KO rats. Together, our findings identify PER1 as a key regulator of synaptic plasticity between diurnal phases in aged rats.
- 28 August 2026
- Published by Wiley in Hippocampus
- Vol. 36 (5)
Open AccessDiurnal Regulation of Hippocampal Synaptic Plasticity in Aged Rats and the Role of the Circadian Clock Gene Per1
Period circadian regulator 1 (PER1) regulates circadian gene expression and is critical for spatial memory. However, its role in regulating synaptic plasticity between diurnal phases remains largely unknown. Here, we examined long‐term potentiation (LTP) and long‐term synaptic depression (LTD) in hippocampal slices prepared from aged male Per1 knockout ( Per1 KO) rats and their wildtype (WT) littermates during the light/inactive and dark/active phases. In WT rats, theta‐burst stimulation (TBS) consistently induced stable LTP that was greater during the dark relative to the light phase. In contrast, in Per1 KO rats, TBS resulted in synaptic potentiation that decayed to baseline levels within ~90 min in both phases. Notably, WT rats readily expressed LTD following 1 Hz low‐frequency stimulation (LFS) during the dark phase but not the light phase. By comparison, in Per1 KO rats, LTD was inducible by LFS during both the dark and light phases. LTD in both WT and Per1 KO rats was dependent on the activation of N ‐methyl‐ d ‐aspartate receptors. Basal synaptic transmission was reduced and GluA1 S845 phosphorylation was increased during the dark phase in both WT and Per1 KO rats. Together, our findings identify PER1 as a key regulator of synaptic plasticity between diurnal phases in aged rats.
- Open Access
- 13 February 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
Visible traits demonstrate that crispant founder mice can be used for phenotypic assessment
Genes can be knocked out in model organisms by introducing a single guide RNA and Cas9 into one cell zygotes. Recently, the zebrafish and Xenopus communities have employed this method in genetic screening pipelines that assess phenotypes in founders (F0), referred to as “crispants”. In contrast, phenotyping crispant mice has been avoided as results are believed to be confounded by genetic mosaicism, requiring that only established mouse lines undergo phenotypic assessment. Here, we targeted seven genes associated with visible recessive phenotypes. We observed the expected null phenotype in up to 100% founders per gene. Crucially, we achieved 100% editing efficiency in all but two animals. Genetic mosaicism was common, but did not confound an animal’s phenotype when comprised of mutations that all disrupted the targeted gene. Mosaicism included short in-frame mutations, but these were sufficient to disrupt function of five genes. Several founders were compound heterozygotes carrying a null and a non-null allele (short in-frame mutation or late truncation), enabling functional assessment of the non-null allele to dissect protein function. Our results set the stage for using crispant founders for initial phenotypic assessment in genetic screening, before selecting candidates for further study. This will dramatically reduce animal numbers.
- 13 February 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
Open AccessVisible traits demonstrate that crispant founder mice can be used for phenotypic assessment
Genes can be knocked out in model organisms by introducing a single guide RNA and Cas9 into one cell zygotes. Recently, the zebrafish and Xenopus communities have employed this method in genetic screening pipelines that assess phenotypes in founders (F0), referred to as “crispants”. In contrast, phenotyping crispant mice has been avoided as results are believed to be confounded by genetic mosaicism, requiring that only established mouse lines undergo phenotypic assessment. Here, we targeted seven genes associated with visible recessive phenotypes. We observed the expected null phenotype in up to 100% founders per gene. Crucially, we achieved 100% editing efficiency in all but two animals. Genetic mosaicism was common, but did not confound an animal’s phenotype when comprised of mutations that all disrupted the targeted gene. Mosaicism included short in-frame mutations, but these were sufficient to disrupt function of five genes. Several founders were compound heterozygotes carrying a null and a non-null allele (short in-frame mutation or late truncation), enabling functional assessment of the non-null allele to dissect protein function. Our results set the stage for using crispant founders for initial phenotypic assessment in genetic screening, before selecting candidates for further study. This will dramatically reduce animal numbers.
- 3 September 2025
- Published by Springer Nature in Nature
- Vol. 645 (8082) , 1029-1038
Genetic suppression features ABHD18 as a Barth syndrome therapeutic target
Cardiolipin (CL) is the signature phospholipid of the inner mitochondrial membrane, where it stabilizes electron transport chain protein complexes1. The final step in CL biosynthesis relates to its remodelling: the exchange of nascent acyl chains with longer, unsaturated chains1. However, the enzyme responsible for cleaving nascent CL (nCL) has remained elusive. Here, we describe ABHD18 as a candidate deacylase in the CL biosynthesis pathway. Accordingly, ABHD18 converts CL into monolysocardiolipin (MLCL) in vitro, and its inactivation in cells and mice results in a shift to nCL in serum and tissues. Notably, ABHD18 deactivation rescues the mitochondrial defects in cells and the morbidity and mortality in mice associated with Barth syndrome. This rare genetic disease is characterized by the build-up of MLCL resulting from inactivating mutations in TAFAZZIN (TAZ), which encodes the final enzyme in the CL-remodelling cascade1. We also identified a selective, covalent, small-molecule inhibitor of ABHD18 that rescues TAZ mutant phenotypes in fibroblasts from human patients and in fish embryos. This study highlights a striking example of genetic suppression of a monogenic disease revealing a canonical enzyme in the CL biosynthesis pathway.
- 3 September 2025
- Published by Springer Nature in Nature
- Vol. 645 (8082) , 1029-1038
Genetic suppression features ABHD18 as a Barth syndrome therapeutic target
Cardiolipin (CL) is the signature phospholipid of the inner mitochondrial membrane, where it stabilizes electron transport chain protein complexes1. The final step in CL biosynthesis relates to its remodelling: the exchange of nascent acyl chains with longer, unsaturated chains1. However, the enzyme responsible for cleaving nascent CL (nCL) has remained elusive. Here, we describe ABHD18 as a candidate deacylase in the CL biosynthesis pathway. Accordingly, ABHD18 converts CL into monolysocardiolipin (MLCL) in vitro, and its inactivation in cells and mice results in a shift to nCL in serum and tissues. Notably, ABHD18 deactivation rescues the mitochondrial defects in cells and the morbidity and mortality in mice associated with Barth syndrome. This rare genetic disease is characterized by the build-up of MLCL resulting from inactivating mutations in TAFAZZIN (TAZ), which encodes the final enzyme in the CL-remodelling cascade1. We also identified a selective, covalent, small-molecule inhibitor of ABHD18 that rescues TAZ mutant phenotypes in fibroblasts from human patients and in fish embryos. This study highlights a striking example of genetic suppression of a monogenic disease revealing a canonical enzyme in the CL biosynthesis pathway.
- Open Access
Tau deletion results in sex-dependent modulation of synaptic weakening in rat hippocampus
Tangles, a defining characteristic of Alzheimer’s disease ( AD ), are composed principally of hyperphosphorylated and misfolded tau species. However, dysregulation of tau precedes tangle formation by many years and is associated with cognitive decline, the best functional correlate of which is synaptic weakening and eventual synaptic loss. Although tau is present at synapses, its normal synaptic function is poorly understood – information vital to the rational development of tau-modifying therapies. Since rats have a greater cognitive repertoire than mice and display more robust signs of tau pathology in AD models, we developed a tau knockout ( Mapt -/- ) rat to investigate the impact of tau elimination on synaptic function. We observed that long-term depression ( LTD ), a form of synaptic weakening, is enhanced in the hippocampus of male, but not female, rats. This enhanced LTD was dependent on the synaptic activation of group I metabotropic glutamate receptors and involved altered synaptic actin polymerization. These studies therefore provide mechanistic insights into how tau modulates synaptic function via regulation of the actin cytoskeleton. Our findings are relevant to the understanding of the physiological roles of synaptic tau, the functional consequences of tau-lowering therapies, and the influence of sex in AD susceptibility.
Open AccessTau deletion results in sex-dependent modulation of synaptic weakening in rat hippocampus
Tangles, a defining characteristic of Alzheimer’s disease ( AD ), are composed principally of hyperphosphorylated and misfolded tau species. However, dysregulation of tau precedes tangle formation by many years and is associated with cognitive decline, the best functional correlate of which is synaptic weakening and eventual synaptic loss. Although tau is present at synapses, its normal synaptic function is poorly understood – information vital to the rational development of tau-modifying therapies. Since rats have a greater cognitive repertoire than mice and display more robust signs of tau pathology in AD models, we developed a tau knockout ( Mapt -/- ) rat to investigate the impact of tau elimination on synaptic function. We observed that long-term depression ( LTD ), a form of synaptic weakening, is enhanced in the hippocampus of male, but not female, rats. This enhanced LTD was dependent on the synaptic activation of group I metabotropic glutamate receptors and involved altered synaptic actin polymerization. These studies therefore provide mechanistic insights into how tau modulates synaptic function via regulation of the actin cytoskeleton. Our findings are relevant to the understanding of the physiological roles of synaptic tau, the functional consequences of tau-lowering therapies, and the influence of sex in AD susceptibility.
- Open Access
Visible traits demonstrate that crispant founder mice can be used for phenotypic assessment
Genes can be knocked out in model organisms by introducing a single guide RNA and Cas9 into one cell zygotes. Recently, the zebrafish and Xenopus communities have employed this method in genetic screening pipelines that assess phenotypes in founders (F0), referred to as “crispants”. In contrast, phenotyping crispant mice has been avoided as results are believed to be confounded by genetic mosaicism, requiring that only established mouse lines undergo phenotypic assessment. Here, we targeted seven genes associated with visible recessive phenotypes. We observed the expected null phenotype in up to 100% founders per gene. Crucially, we achieved 100% editing efficiency in all but two animals. Genetic mosaicism was common, but did not confound an animal’s phenotype when comprised of mutations that all disrupted the targeted gene. Mosaicism included short in-frame mutations, but these were sufficient to disrupt function of five genes. Several founders were compound heterozygotes carrying a null and a non-null allele (short in-frame mutation or late truncation), enabling functional assessment of the non-null allele to dissect protein function. Our results set the stage for using crispant founders for initial phenotypic assessment in genetic screening, before selecting candidates for further study. This will dramatically reduce animal numbers.
Open AccessVisible traits demonstrate that crispant founder mice can be used for phenotypic assessment
Genes can be knocked out in model organisms by introducing a single guide RNA and Cas9 into one cell zygotes. Recently, the zebrafish and Xenopus communities have employed this method in genetic screening pipelines that assess phenotypes in founders (F0), referred to as “crispants”. In contrast, phenotyping crispant mice has been avoided as results are believed to be confounded by genetic mosaicism, requiring that only established mouse lines undergo phenotypic assessment. Here, we targeted seven genes associated with visible recessive phenotypes. We observed the expected null phenotype in up to 100% founders per gene. Crucially, we achieved 100% editing efficiency in all but two animals. Genetic mosaicism was common, but did not confound an animal’s phenotype when comprised of mutations that all disrupted the targeted gene. Mosaicism included short in-frame mutations, but these were sufficient to disrupt function of five genes. Several founders were compound heterozygotes carrying a null and a non-null allele (short in-frame mutation or late truncation), enabling functional assessment of the non-null allele to dissect protein function. Our results set the stage for using crispant founders for initial phenotypic assessment in genetic screening, before selecting candidates for further study. This will dramatically reduce animal numbers.
- Open Access
A Rosella-PLIN2 Knock-in Mouse Reveals Lipophagy and Immunometabolic Interplay in Atherosclerosis
Cytosolic lipid droplets (LDs) regulate lipid homeostasis, with abnormal LD dynamics linked to metabolic diseases like atherosclerosis. In macrophage foam cells, LDs undergo autophagic degradation via lipophagy, but the extent of this process in vascular smooth muscle cell (VSMC) foam cells remains unclear. To track lipophagy in real time, we developed a Rosella-PLIN2 biosensor by tagging perilipin 2 (PLIN2) with the fluorescent pH-biosensor Rosella. We show that proatherogenic lipoproteins and autophagy activators stimulate lipophagy in human macrophages. Targeting LDs with an LC3 fusion protein or LD-autophagy tethering compounds (LD-ATTECs) selectively enhanced lipophagy, promoting foam cell LD clearance. In an atherosclerosis model, Rosella-PLIN2 accurately tracked lipophagy in arterial foam cells, revealing distinct PLIN2 expression patterns in macrophage and non-leukocyte foam cells. We identified a lipophagy deficiency in VSMC foam cells and demonstrate that enhancing lipophagy promotes LD catabolism in primary VSMC foam cells. TREM2 + macrophages exhibited high lipid content and low lipophagy flux, whereas TREM2 - macrophages had low lipid content and high lipophagy flux. Our findings highlight a cell-specific interplay between lipophagy and immunometabolism in arterial foam cells, unveiling novel therapeutic avenues for atherosclerosis. Additionally, the Rosella-PLIN2 model provides a powerful tool for studying LD metabolism, offering new insights into lipid homeostasis and disease mechanisms.
Open AccessA Rosella-PLIN2 Knock-in Mouse Reveals Lipophagy and Immunometabolic Interplay in Atherosclerosis
Cytosolic lipid droplets (LDs) regulate lipid homeostasis, with abnormal LD dynamics linked to metabolic diseases like atherosclerosis. In macrophage foam cells, LDs undergo autophagic degradation via lipophagy, but the extent of this process in vascular smooth muscle cell (VSMC) foam cells remains unclear. To track lipophagy in real time, we developed a Rosella-PLIN2 biosensor by tagging perilipin 2 (PLIN2) with the fluorescent pH-biosensor Rosella. We show that proatherogenic lipoproteins and autophagy activators stimulate lipophagy in human macrophages. Targeting LDs with an LC3 fusion protein or LD-autophagy tethering compounds (LD-ATTECs) selectively enhanced lipophagy, promoting foam cell LD clearance. In an atherosclerosis model, Rosella-PLIN2 accurately tracked lipophagy in arterial foam cells, revealing distinct PLIN2 expression patterns in macrophage and non-leukocyte foam cells. We identified a lipophagy deficiency in VSMC foam cells and demonstrate that enhancing lipophagy promotes LD catabolism in primary VSMC foam cells. TREM2 + macrophages exhibited high lipid content and low lipophagy flux, whereas TREM2 - macrophages had low lipid content and high lipophagy flux. Our findings highlight a cell-specific interplay between lipophagy and immunometabolism in arterial foam cells, unveiling novel therapeutic avenues for atherosclerosis. Additionally, the Rosella-PLIN2 model provides a powerful tool for studying LD metabolism, offering new insights into lipid homeostasis and disease mechanisms.
- Open Access
Assigning Targetable Molecular Pathways to Transdiagnostic Subgroups Across Autism and Related Neurodevelopmental Disorders
Significant genetic, behavioural and neuroanatomic heterogeneity is common in autism spectrum- and related- neurodevelopmental disorders (NDDs). This heterogeneity constrains the development of effective therapies for diverse patients in precision medicine paradigms. This has led to the search for subgroups of individuals having common etiologic factors/biology (e.g., genetic pathways), thus creating potential uniformity in prognosis and/or treatment response. Despite NDDs having a strong genetic component, only ~15-20% of individuals will present with a specific rare genetic variant considered clinically pathogenic, and therefore, subtyping efforts tend to focus on using clinical, cognitive, and/or brain imaging phenotypes to group individuals. Here we delineated mechanisms via mouse to human translational neuroscience. Using MRI derived structural neuroanatomy and a spatial transcriptomic comparison, we linked subgroups of 135 NDD relevant mouse models (3,515 individual mice) separately to two human databases, with 1,234 and 1,015 human individuals with NDDs, composed of autism, attention-deficit/hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), other related NDDs, and typically developing controls. Subgroups were significantly linked by consistent neuroanatomy across all three datasets, mouse and human, indicating that direct cross-species subgrouping and translation is consistent and reproducible. Ultimately, four specific neuroanatomical clusters were found and linked to precise molecular mechanisms: two showing a chromatin/transcription motif, with one of those showing specific links to G-protein coupled receptors (GPCR) and Notch signalling, and another two being mainly synaptic in origin, with one off those showing specific connections to axon guidance and Wnt signaling. Assigning molecular pathways, and thus genetic information, from the mouse to individual participants provides an insight into undetected and/or related genetic variants that could be working in combination or interacting with an environmental influence. Moreover, the subgroups found are transdiagnostic, including participants with autism, ADHD, and OCD, which indicates that NDDs as a whole can be subdivided into consistent neuroanatomical clusters with cohesive underlying biological mechanisms. This work allows us to bridge the gap between preclinical models and human disorders, linking previously idiopathic human patients to pertinent genetics, molecular mechanisms, and pathways.
Open AccessAssigning Targetable Molecular Pathways to Transdiagnostic Subgroups Across Autism and Related Neurodevelopmental Disorders
Significant genetic, behavioural and neuroanatomic heterogeneity is common in autism spectrum- and related- neurodevelopmental disorders (NDDs). This heterogeneity constrains the development of effective therapies for diverse patients in precision medicine paradigms. This has led to the search for subgroups of individuals having common etiologic factors/biology (e.g., genetic pathways), thus creating potential uniformity in prognosis and/or treatment response. Despite NDDs having a strong genetic component, only ~15-20% of individuals will present with a specific rare genetic variant considered clinically pathogenic, and therefore, subtyping efforts tend to focus on using clinical, cognitive, and/or brain imaging phenotypes to group individuals. Here we delineated mechanisms via mouse to human translational neuroscience. Using MRI derived structural neuroanatomy and a spatial transcriptomic comparison, we linked subgroups of 135 NDD relevant mouse models (3,515 individual mice) separately to two human databases, with 1,234 and 1,015 human individuals with NDDs, composed of autism, attention-deficit/hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), other related NDDs, and typically developing controls. Subgroups were significantly linked by consistent neuroanatomy across all three datasets, mouse and human, indicating that direct cross-species subgrouping and translation is consistent and reproducible. Ultimately, four specific neuroanatomical clusters were found and linked to precise molecular mechanisms: two showing a chromatin/transcription motif, with one of those showing specific links to G-protein coupled receptors (GPCR) and Notch signalling, and another two being mainly synaptic in origin, with one off those showing specific connections to axon guidance and Wnt signaling. Assigning molecular pathways, and thus genetic information, from the mouse to individual participants provides an insight into undetected and/or related genetic variants that could be working in combination or interacting with an environmental influence. Moreover, the subgroups found are transdiagnostic, including participants with autism, ADHD, and OCD, which indicates that NDDs as a whole can be subdivided into consistent neuroanatomical clusters with cohesive underlying biological mechanisms. This work allows us to bridge the gap between preclinical models and human disorders, linking previously idiopathic human patients to pertinent genetics, molecular mechanisms, and pathways.
- Open Access
- 25 February 2025
- Published by Wiley in Current Protocols
- Vol. 5 (2) , e70109
Engineering Base Changes and Epitope‐Tagged Alleles in Mice Using Cas9 RNA‐Guided Nuclease
Mice carrying patient‐associated base changes are powerful tools to define the causality of single‐nucleotide variants to disease states. Epitope tags enable immuno‐based studies of genes for which no antibodies are available. These alleles enable detailed and precise developmental, mechanistic, and translational research. The first step in generating these alleles is to identify within the target sequence—the orthologous sequence for base changes or the N or C terminus for epitope tags—appropriate Cas9 protospacer sequences. Subsequent steps include design and acquisition of a single‐stranded oligonucleotide repair template, synthesis of a single guide RNA (sgRNA), collection of zygotes, and microinjection or electroporation of zygotes with Cas9 mRNA or protein, sgRNA, and repair template followed by screening born mice for the presence of the desired sequence change. Quality control of mouse lines includes screening for random or multicopy insertions of the repair template and, depending on sgRNA sequence, off‐target sequence variation introduced by Cas9. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Single guide RNA design and synthesis Alternate Protocol 1 : Single guide RNA synthesis by primer extension and in vitro transcription Basic Protocol 2 : Design of oligonucleotide repair template Basic Protocol 3 : Preparation of RNA mixture for microinjection Support Protocol 1 : Preparation of microinjection buffer Alternate Protocol 2 : Preparation of RNP complexes for electroporation Basic Protocol 4 : Collection and preparation of mouse zygotes for microinjection or electroporation Basic Protocol 5 : Electroporation of Cas9 RNP into zygotes using cuvettes Alternate Protocol 3 : Electroporation of Cas9 RNP into zygotes using electrode slides Basic Protocol 6 : Screening and quality control of derived mice Support Protocol 2 : Deconvoluting multiple sequence chromatograms with DECODR
- 25 February 2025
- Published by Wiley in Current Protocols
- Vol. 5 (2) , e70109
Open AccessEngineering Base Changes and Epitope‐Tagged Alleles in Mice Using Cas9 RNA‐Guided Nuclease
Mice carrying patient‐associated base changes are powerful tools to define the causality of single‐nucleotide variants to disease states. Epitope tags enable immuno‐based studies of genes for which no antibodies are available. These alleles enable detailed and precise developmental, mechanistic, and translational research. The first step in generating these alleles is to identify within the target sequence—the orthologous sequence for base changes or the N or C terminus for epitope tags—appropriate Cas9 protospacer sequences. Subsequent steps include design and acquisition of a single‐stranded oligonucleotide repair template, synthesis of a single guide RNA (sgRNA), collection of zygotes, and microinjection or electroporation of zygotes with Cas9 mRNA or protein, sgRNA, and repair template followed by screening born mice for the presence of the desired sequence change. Quality control of mouse lines includes screening for random or multicopy insertions of the repair template and, depending on sgRNA sequence, off‐target sequence variation introduced by Cas9. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Single guide RNA design and synthesis Alternate Protocol 1 : Single guide RNA synthesis by primer extension and in vitro transcription Basic Protocol 2 : Design of oligonucleotide repair template Basic Protocol 3 : Preparation of RNA mixture for microinjection Support Protocol 1 : Preparation of microinjection buffer Alternate Protocol 2 : Preparation of RNP complexes for electroporation Basic Protocol 4 : Collection and preparation of mouse zygotes for microinjection or electroporation Basic Protocol 5 : Electroporation of Cas9 RNP into zygotes using cuvettes Alternate Protocol 3 : Electroporation of Cas9 RNP into zygotes using electrode slides Basic Protocol 6 : Screening and quality control of derived mice Support Protocol 2 : Deconvoluting multiple sequence chromatograms with DECODR
- Open Access
- 30 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Impact of essential genes on the success of genome editing experiments generating 3313 new genetically engineered mouse lines
The International Mouse Phenotyping Consortium (IMPC) systematically produces and phenotypes mouse lines with presumptive null mutations to provide insight into gene function. The IMPC now uses the programmable RNA-guided nuclease Cas9 for its increased capacity and flexibility to efficiently generate null alleles in the C57BL/6N strain. In addition to being a valuable novel and accessible research resource, the production of 3313 knockout mouse lines using comparable protocols provides a rich dataset to analyze experimental and biological variables affecting in vivo gene engineering with Cas9. Mouse line production has two critical steps – generation of founders with the desired allele and germline transmission (GLT) of that allele from founders to offspring. A systematic evaluation of the variables impacting success rates identified gene essentiality as the primary factor influencing successful production of null alleles. Collectively, our findings provide best practice recommendations for using Cas9 to generate alleles in mouse essential genes, many of which are orthologs of genes linked to human disease.
- 30 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Open AccessImpact of essential genes on the success of genome editing experiments generating 3313 new genetically engineered mouse lines
The International Mouse Phenotyping Consortium (IMPC) systematically produces and phenotypes mouse lines with presumptive null mutations to provide insight into gene function. The IMPC now uses the programmable RNA-guided nuclease Cas9 for its increased capacity and flexibility to efficiently generate null alleles in the C57BL/6N strain. In addition to being a valuable novel and accessible research resource, the production of 3313 knockout mouse lines using comparable protocols provides a rich dataset to analyze experimental and biological variables affecting in vivo gene engineering with Cas9. Mouse line production has two critical steps – generation of founders with the desired allele and germline transmission (GLT) of that allele from founders to offspring. A systematic evaluation of the variables impacting success rates identified gene essentiality as the primary factor influencing successful production of null alleles. Collectively, our findings provide best practice recommendations for using Cas9 to generate alleles in mouse essential genes, many of which are orthologs of genes linked to human disease.